核心技術

CancerFree
Jun 7, 2022

精拓的獨家技術是將血液中極少量的循環腫瘤細胞通過獨有的細胞培養系統快速大量的擴增,並進行各項個人化分析。與目前市場上其他技術相比,通過血液採集檢體更加方便且安全。

◎ E.V.A. 技術介紹
首個提供臨床應用的腫瘤細胞培養系統
專利的3D仿生支架能夠模擬體內環境,促進腫瘤細胞增殖並維持其異質性

- 高培養成功率:成功率超過90%,並已成功培養超過 100 種癌症類型
- 高效率:可再4週內擴增1,000~100,000倍
- 超過900個成功案例
- 超過100種FDA核准之抗癌藥物可供選擇測試

與其他腫瘤培養實驗室比較
培養出之腫瘤細胞螢光染色鑑定

◎ 已發表文獻

Ex Vivo Expansion and Drug Sensitivity Profiling of Circulating Tumor Cells from Patients with Small Cell Lung Cancer

Ex Vivo Expanded Circulating Tumor Cells for Clinical Anti-Cancer Drug Prediction in Patients with Head and Neck Cancer

Circulating tumor cells (CTC)-derived organoids for clinical anticancer drug prediction

Patient-Derived Tumor Chemosensitization of GKB202, an Antrodia Cinnamomea Mycelium-Derived Bioactive Compound

Correlation between drug sensitivity profiles ofcirculating tumour cell-derived organoids and clinicaltreatment response in patients with pancreatic ductaladenocarcinoma

--

--